Veru Announces Sabizabulin Data Shows It Can Overcome Drug Resistance To Daraxonrasib With Potent Anticancer Efficacy
Veru Inc. (NASDAQ: VERU) today announces new preclinical data showing that sabizabulin can overcome drug resistance to daraxonrasib (RASONQUE™1 Revolution Medicines) with potent anticancer efficacy (IC50=18.2nM) in
Veru found that their medicine sabizabulin works really well against cancer cells that stopped responding to another company's drug. This shows their medicine might help patients when other treatments stop working.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.